Calciscon AG is a Swiss startup company develops and commecializes the first and the only diagnostic blood test for the assessment of the formation of crystalline phosphate particles in blood. This new blood test is mainly for the kidney diasease patients (i.e. Chronic kidney disease, dialysis and renal transplant patients). These patients are at very high cardiovascular risk and have a vastly reduced life expectancy. Calciscon’s T50-Test is future diagnostic standard test for kidney patients and will help to identify patients at high risk and monitor and guide treatments with available drugs.
Company’s Keywords:
<8
<
<2013
Your request has been submitted successfully.
Own or work here?